制度・支援
指定難病 — No.300

IgG4関連疾患

検索語 IgG4-Related Disease ・ 最終更新 2026-07-21 20:56 ・ 最新に更新

Data Sheet
指定 No.300
Src PubMed · CT.gov · jRCT

これは医療アドバイスではありません。診断・治療の判断は必ず主治医にご相談ください。論文や治験は「今わかっている研究の状況」を示すもので、効果を保証するものではありません。

( 01 )EVIDENCE / PUBMED · 5件

世界の論文

直近の研究を、やさしい日本語で

各論文の見出しにある「確からしさ」は、その研究がどれくらい信頼できるかの目安です。「理論段階」はまだ仮説に近く、下にいくほど多くの患者で検証されていて、「メタ解析」がもっとも信頼できます。

不明
MK-01 · PMID 42469411

IgG4-Related Hepatic Disease Unmasking Hepatic Actinomycosis

Abstract / 原文

PURPOSE: Hepatic actinomycosis is a rare granulomatous disease caused by an opportunistic Gram-positive bacillus of the genus Actinomyces. We report an unusual association between hepatic actinomycosis and IgG-4 related disease. CASE DESCRIPTION: A 70-year-old man was admitted to the University Hospital of Reunion Island for asthenia and abdominal pain. Laboratory tests showed hepatic cholestasis and inflammatory reaction without cytolysis. The computer tomography scanner (CT scan) revealed a large hepatic mass in segment IV. IgG4 related disease (IgG4-RD) was diagnosed following liver biopsy. Despite the use of corticosteroids, the lesions progressed. A new biopsy was performed and a PCR test returned positive for Actinomyces spp. We observed patient improvement after 4 months of treatment with amoxicillin and discontinuation of corticosteroids. CONCLUSIONS: Clinical presentation, imaging characteristics, and diagnostic challenges are strikingly similar between hepatic actinomycosis and IgG4-related disease. However, distinguishing between these two disorders is essential - as the treatment of one may worsen the course of the other. Knowing and understanding the interactions between these two disorders can only be achieved through an integrated and collaborative approach involving various disciplines.

Journal
Journal of clinical immunology(2026 Jul)
Authors
5名
Type
Journal Article
PubMedで原文を見る
基礎研究(細胞・動物など)
MK-02 · PMID 42468516

Epitrochlear Kimura Disease With Concurrent Prurigo Nodularis

Abstract / 原文

Kimura disease typically presents with painless head and neck swelling in young adults of Asian descent, accompanied by peripheral eosinophilia and elevated serum IgE. We report a case of Kimura disease in a woman in her early 30s presenting with a slowly enlarging epitrochlear mass, diffuse encasement of the median and medial brachial cutaneous nerves, and a concurrent prurigo nodularis-like papular rash affecting all 4 extremities. The diagnosis required over 1 year of investigation and 5 tissue specimens, including 2 nondiagnostic core-needle biopsies, before near total excision was performed. The excision revealed characteristic histopathologic features, including hyperplastic reactive secondary lymphoid follicles with preserved architecture, a marked eosinophilic infiltrate with eosinophilic microabscesses, postcapillary venule proliferation, and patternless stromal fibrosis. Immunohistochemistry demonstrated a raised IgG4:IgG plasma cell ratio of approximately 1:1, with 150-200 IgG4-positive plasma cells per high-power field, raising the differential of IgG4-related disease; however, the absence of storiform fibrosis and obliterative phlebitis, combined with the clinical and serologic profile, favored Kimura disease. This case is notable for its rare epitrochlear location, extensive neural involvement, concurrent diffuse cutaneous eruption, and histopathologic overlap with IgG4-related disease, highlighting the diagnostic challenges posed by atypical presentations of Kimura disease.

Journal
The American Journal of dermatopathology(2026 Jul)
Authors
5名
Type
Journal Article
PubMedで原文を見る
不明
MK-03 · PMID 42463108

Photo essayInfraorbital fog light sign: bilateral infraorbital nerve thickening and enhancement in IgG4-related ophthalmic disease

Journal
Canadian journal of ophthalmology. Journal canadien d'ophtalmologie(2026 Jul)
Authors
3名
Type
Journal Article
PubMedで原文を見る
不明
MK-04 · PMID 42461436

Anti-Toxocara canis seroreactivity across autoimmune rheumatic diseases with exploratory IgG4 and eosinophil-associated signals in systemic lupus erythematosus: a cross-sectional case-control study

Abstract / 原文

Helminth-related immune responses may intersect with autoimmune rheumatic diseases, but disease-specific patterns remain incompletely understood. This study aimed to investigate anti-Toxocara canis seroreactivity and its immunological and clinical correlates in rheumatoid arthritis, systemic lupus erythematosus, and spondyloarthritis. In this cross-sectional case-control study, 442 individuals were evaluated across disease-specific comparisons. Serology followed a sequential strategy using native T. canis excretory-secretory antigen for initial IgG screening and a recombinant chimeric antigen for confirmatory IgG, IgG1, and IgG4 assessment. Cytokines, eosinophil counts, socioeconomic variables, disease activity, and functional disability were analyzed using adjusted regression models. Total anti-T. canis IgG seroreactivity was frequent across groups. Higher adjusted point estimates were observed in rheumatoid arthritis, systemic lupus erythematosus, and spondyloarthritis. SLE was the only disease group showing a nominally significant association with IgG seroreactivity compared with its respective control group (OR 2.44, 95% CI 1.16-5.14), although no serological association remained significant after FDR correction. SLE also showed a nominal signal of lower IgG4 seroreactivity than controls in the standard adjusted model (OR 0.20, 95% CI 0.04-0.99), but this finding did not remain significant after FDR correction or in small-cell sensitivity analyses. Higher eosinophil counts were associated with lower SLEDAI scores in negative binomial models (IRR per 100 eosinophils/mm³: 0.56, 95% CI 0.36-0.86), and this association persisted after adjustment for medication use, although it should be interpreted as exploratory given the low SLEDAI distribution and limited number of active disease events. Anti-T. canis seroreactivity was frequent across autoimmune rheumatic diseases and showed disease-specific exploratory patterns. In SLE, higher total IgG seroreactivity coexisted with a cautious, hypothesis-generating IgG4 signal, while eosinophil counts showed an exploratory independent association with lower SLEDAI scores. These findings suggest that helminth-related immune signatures may vary across autoimmune disease contexts and should be interpreted as exploratory associations rather than evidence of active infection or causal immunomodulation.

利益相反の可能性特許の出願人/保有者である記載あり
Journal
Rheumatology international(2026 Jul)
Authors
15名
Type
Journal Article
PubMedで原文を見る
症例報告
MK-05 · PMID 42460177

A Rare Presentation of Acute Cholecystitis Mimicking Malignancy in a Young Male With Elevated IgG4

Abstract / 原文

A rare case of a 26-year-old male presenting with abdominal pain and jaundice was initially suspected to be a gallbladder malignancy based on imaging findings of a gallbladder fossa mass and biliary strictures. Serial imaging, including ultrasound, CT, PET-CT, and endoscopic retrograde cholangiopancreatography (ERCP), revealed a hypermetabolic mass with biliary obstruction but no gallstones. Elevated serum IgG4 levels and a marked clinical response to steroids led to the diagnosis of IgG4-related sclerosing cholangitis (IgG4-SC) and cholecystitis, an uncommon presentation that often mimics malignancy or acute cholecystitis. This case highlights the diagnostic challenges and importance of considering IgG4-related disease (IgG4-RD) in young patients with inflammatory biliary masses and emphasizes multidisciplinary management to avoid unnecessary surgery.

Journal
Cureus(2026 Jun)
Authors
2名
Type
Case Reports, Journal Article
PubMedで原文を見る
( 02 )TRIALS / JAPAN · 2件

日本で参加できる治験

現在 募集中のもの

各治験の「対象の目安」は年齢などの参加条件の一部です。ここに合っていても他の条件(病状・治療歴など)があります。詳しい参加条件は各治験ページで確認し、参加の可否は必ず主治医とご相談ください。

募集中
TR-01 · NCT07061938

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

Phase
PHASE1 / PHASE2
対象の目安
18歳〜75歳
Country
日本・アメリカ
詳細・参加条件を見る
募集中
TR-02 · NCT07190196

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

Phase
PHASE3
対象の目安
18歳以上
Country
日本・Saudi Arabia・アメリカ・アルゼンチン・イギリス・イスラエル・イタリア・オランダ・カナダ・スウェーデン・スペイン・チリ・ドイツ・フランス・ベルギー・ポーランド・中国・台湾・韓国
詳細・参加条件を見る
( 03 )REGISTRY / jRCT

治験をもっと探す

日本の公式レジストリで全件を確認

上の一覧は ClinicalTrials.gov の一部です。日本国内の治験の多くは、日本の公式レジストリ jRCT にのみ登録されています。下記から最新の全件をご確認ください。

※ jRCTは自動の大量データ取得を禁じているため、本サービスはjRCTを自動収集せず、患者ご自身が公式サイトで検索できるリンクでご案内しています(規約順守)。

お金・介護・制度IgG4関連疾患の療養に使えるかもしれない公的サポートを調べる医療費・生活費・介護の支援制度と相談先を、あなたの状況に合わせてご案内(回答は端末内で完結)
( 04 )SUPPORT

患者会・相談窓口

一人で抱え込まないでください

同じ病気の患者・家族とつながる、制度や生活の相談をする、といったときの窓口です。

全国の相談先

※ お住まいの都道府県の「難病相談支援センター」でも、医療費助成や療養生活の相談ができます(難病情報センターから探せます)。